So-Young International (SY) Q2 2026: Aesthetic Treatment Revenues Surge 130%, Driving Margin Expansion and Operational Efficiency
So-Young’s aesthetic treatment segment delivered robust growth with a 130% year-over-year revenue surge, underpinning a record quarterly revenue and a 3.8 percentage point gross margin expansion. Operational enhancements and AI integration reinforced efficiency gains as the branded clinic network scaled to 65 centers across 18 cities. Management’s disciplined expansion and strategic upstream partnerships set the stage for sustainable margin improvement and approaching profitability.
Summary
- Clinic Network Scale and Efficiency: Expansion to 65 centers with 47 profitable and 51 generating positive cash flow.
- AI-Driven Operational Enhancements: Integration of AI in medical delivery and supply chain management improving uniformity and customer trust.
- Strategic Upstream Collaboration: Data-driven co-creation with suppliers enhancing product innovation and supply chain competitiveness.
Business Overview
So-Young International operates as a leading aesthetic treatment platform in China, connecting consumers to medical aesthetic services through online channels and offline branded clinics. The company’s revenue streams include aesthetic treatment services, information and reservation services, sales of medical products and maintenance, and other services such as insurance brokerage. The branded aesthetic centers, operating under the So-Young Clinic network, represent the core growth engine, delivering high-touch medical aesthetic treatments supported by a growing user base and proprietary product collaborations.
Performance Analysis
In the second quarter of 2026, So-Young posted total revenues of RMB 505.2 million, a 33.4% increase year-over-year, driven predominantly by the aesthetic treatment services segment which surged 129.5% to RMB 331.4 million. This segment now constitutes the majority of the company’s revenue and reflects the success of the clinic expansion strategy. Despite the rapid growth, the company improved its gross margin by 3.8 percentage points to 28.1%, highlighting operational leverage and efficiency gains across the network.
Other segments such as information and reservation services, medical product sales, and other services experienced declines, reflecting a strategic shift in focus towards the scalable and high-margin branded aesthetic centers. Operating expenses rose modestly by 10.4%, with sales and marketing costs increasing to support brand building and user acquisition, while research and development expenses declined due to improved staff efficiency. The company narrowed its net loss attributable to shareholders by 37% to RMB 22.7 million, underscoring improved unit economics and disciplined cost management.
- Clinic Expansion Impact: Addition of 11 new centers to reach 65 clinics, with 47 centers profitable and 51 generating positive cash flow.
- Revenue Mix Shift: Aesthetic treatment services now dominate revenue, offsetting declines in legacy segments.
- Margin Expansion Drivers: Increased bed utilization and streamlined workflows lifted gross margin despite rapid scale.
Overall, the company demonstrated a clear inflection towards profitable growth, validating its dual focus on scale and operational excellence within the core aesthetic treatment business.
Executive Commentary
"Our sustained focus on scale and efficiency yielded another strong quarter for our core aesthetic treatment business. Supported by enhanced medical capabilities, a robust standardized delivery system, and deeper AI integration, we scaled our business more efficiently. This solid execution is validated by a 129.5% year-over-year increase in second-quarter aesthetic treatment services revenues with a 3.8 percentage-point expansion in segment gross margin. Going forward, we will further strengthen our supply chain and accelerate AI-powered transformation to deliver more competitive products and services across our expanding network, laying a solid foundation for sustainable, high-quality growth."
Xing Jin, Founder, Chairman and Chief Executive Officer
"In the second quarter of 2026, our aesthetic treatment business exceeded RMB 330 million in revenue, representing approximately 130% year-over-year growth and marking the tenth consecutive quarter of triple-digit expansion. This strong performance propelled our second-quarter total revenues to an all-time high of RMB 505.2 million, up 33.4% year-over-year. While maintaining this rapid topline growth, we have remained highly focused on expansion quality and sustainability, striving for healthier unit economics and narrowing net loss attributable to the Company by 37.0% year-over-year. These results reaffirmed both our market insights and execution excellence, as we continued to enhance our medical service delivery, organizational capabilities, and supply chain management, while improving operational efficiency."
Shen Wusheng, Chief Financial Officer
Strategic Positioning
1. Clinic Network Scale and Profitability Focus
So-Young’s expansion to 65 branded aesthetic centers across 18 major cities reflects a disciplined growth strategy balancing scale with profitability. With 47 centers profitable and 51 generating positive operating cash flow, the company is unlocking economies of scale while improving operational efficiency. The ramp-up period for new centers is shortening, contributing to same-store sales growth of 52% year-over-year, a significant acceleration from 14% in the prior year.
2. AI Integration to Standardize Medical Delivery
The company is pioneering AI applications to transform experience-driven medical aesthetic procedures into standardized, visible, and replicable processes. AI supports quality control, physician training, and treatment uniformity, enhancing user trust and safety. Planned large-scale AI deployment across the clinic network in Q4 2026 aims to further improve operational consistency and customer experience.
3. Data-Driven Upstream Partnerships and Product Innovation
So-Young has evolved its supplier relationships into strategic co-creation partnerships, leveraging real-world data to inform product development and optimize inventory. Collaborations with upstream manufacturers like Jingbo Biopharmaceuticals enable joint innovation and supply chain leverage, supporting competitive pricing and a robust product pipeline that underpins future margin expansion.
4. Operational Efficiency and Unit Economics Enhancement
Through higher bed utilization targets—raising treatment points per bed by 50%—and optimized workflows, So-Young is improving labor productivity and customer throughput. These changes reduce client wait times and unlock operating leverage, directly contributing to gross margin improvement and narrowing net losses despite rapid expansion.
5. Focused Capital Allocation and Portfolio Optimization
The company is prioritizing investment in its core clinic business while scaling back or exiting less profitable segments such as information services and insurance brokerage. This focus enhances resource allocation, supporting sustainable growth and profitability in the high-potential branded aesthetic treatment segment.
Key Considerations
So-Young’s second quarter results underscore a strategic pivot towards scalable, high-margin aesthetic treatment services supported by operational rigor and technology adoption. Key considerations for investors include:
- Clinic Profitability Trajectory: The increasing number of profitable centers and positive operating cash flow signals nearing breakeven at the chain level, a critical milestone for investor returns.
- AI as a Differentiator: The company’s early and broad AI integration in clinical workflows and supply chain management may create sustainable competitive advantages in quality and efficiency.
- Supply Chain Leverage: Strategic upstream partnerships and data-driven product development reduce procurement costs and enhance product offerings, supporting margin growth.
- Customer Acquisition Efficiency: Over 50% of new customers come from existing user referrals, lowering acquisition costs and enhancing customer lifetime value (LTV).
- Revenue Mix Shift Risks: Declines in legacy segments highlight the company’s dependence on the aesthetic treatment business, which must sustain growth and profitability to offset those declines.
Risks
Risks include the challenges of scaling medical services while maintaining quality and safety, regulatory changes in China’s medical aesthetics market, and competitive pressures from other providers. Execution risks around AI implementation and supply chain partnerships could affect operational efficiency and margin expansion. Additionally, dependence on a limited number of upstream partners may expose the company to supply disruptions or pricing pressure.
Forward Outlook
For the third quarter of 2026, So-Young expects aesthetic treatment services revenues between RMB 352 million and RMB 362 million, representing year-over-year growth of approximately 92% to 97%. Management emphasized that this outlook reflects current market conditions and anticipates continued operational improvements and margin gains. The company plans to maintain disciplined expansion, further AI integration, and deepen supply chain collaborations to drive sustainable growth.
Takeaways
So-Young is executing a clear strategic transformation, leveraging scale, operational discipline, and technology to convert rapid revenue growth into improving profitability. The clinic network’s expansion and efficiency gains underpin the shift to sustainable unit economics, while innovative upstream partnerships and AI adoption position the company to maintain competitive advantages in a growing market.
- Clinic Network Profitability Emerges: With nearly 75% of centers profitable and positive cash flow generation expanding, So-Young’s core business is approaching a critical inflection point toward breakeven and earnings leverage.
- Technology-Enabled Quality and Efficiency: AI-driven standardization and real-time quality control enhance medical delivery consistency, supporting customer trust and operational scalability.
- Strategic Partnerships Fuel Innovation: Data-informed co-creation with upstream suppliers accelerates product development and cost competitiveness, critical for margin expansion amid rapid growth.
Conclusion
So-Young’s Q2 2026 results demonstrate strong execution in scaling its branded aesthetic treatment business with improving profitability metrics. The company’s integration of AI and strategic upstream collaborations signal a forward-looking approach to sustaining growth and operational excellence. Investors should monitor clinic profitability trends and AI deployment progress as key indicators of the company’s path to long-term value creation.
Industry Read-Through
So-Young’s robust growth and margin improvement reflect broader trends in China’s medical aesthetics sector, where consolidation, technology adoption, and supply chain innovation are reshaping competitive dynamics. The company’s AI-enabled standardization efforts and data-driven supplier partnerships provide a model for other players aiming to balance rapid expansion with quality and profitability. Additionally, the shift towards natural restoration and long-term treatment efficacy, as evidenced by So-Young’s product collaborations, signals evolving consumer preferences that industry participants should anticipate and address.